Wright Bonilla Quoted on DOJ Brief
November 5, 2010
BNA’s Patent, Trademark & Copyright Journal
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BNA’s Patent, Trademark & Copyright Journal on November 5, 2010 titled “DOJ’s ‘Questionable Reinterpretation’ of DNA Patentability Disappoints Patent Community.” Wright Bonilla discusses the patent community’s backlash against a brief filed by the U.S. Department of Justice as a friend of the court in the Myriad case on the patentability of genetic materials. She cautions against an overreaction to the DOJ’s brief, stating that Myriad’s composition claims directed to cDNA are patent eligible. She adds that the DOJ brief asserts this patent eligibility and meets the threshold of Section 101 of the Patent Act.
Related News
March 2, 2026
In the News
Gustavo Resendiz Assesses Challenges of Private Equity Fundraising
Foley & Lardner LLP partner Gustavo Resendiz examined the challenges of private equity fundraising in the Mergers & Acquisitions article, “The State of Middle Market Fundraising.”
February 25, 2026
In the News
Susan Poll Klaessy Details Restructuring Landscape in Podcast Appearance – 'The band-aids are starting to come off'
Foley & Lardner LLP partner Susan Poll Klaessy appeared on the M&A Advisor podcast to discuss the current business restructuring landscape.
February 20, 2026
In the News
Gregory Husisian Weighs in on Impact, Next Steps in Wake of SCOTUS Tariff Ruling
Foley & Lardner LLP partner Gregory Husisian generated widespread media coverage discussing the SCOTUS ruling that President Donald Trump improperly used the International Emergency Powers Act (IEEPA) to impose tariffs.